

# Jonel Trebicka

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5759394/jonel-trebicka-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

300  
papers

12,971  
citations

55  
h-index

106  
g-index

359  
ext. papers

17,087  
ext. citations

6.7  
avg, IF

6.41  
L-index

#	Paper	IF	Citations
300	Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. <i>Gastroenterology</i> , <b>2013</b> , 144, 1426-37, 1437.e1-9	13.3	1525
299	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 406-460	13.4	930
298	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1038-47	13.4	512
297	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , <b>2016</b> , 64, 1249-64	11.2	349
296	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , <b>2015</b> , 62, 243-52	11.2	342
295	Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. <i>Hepatology</i> , <b>2010</b> , 51, 210-8	11.2	342
294	Etiology, management, and outcome of the Budd-Chiari syndrome. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 167-75	8	329
293	Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. <i>Hepatology</i> , <b>2007</b> , 46, 242-53	11.2	234
292	Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. <i>Fibrogenesis and Tissue Repair</i> , <b>2013</b> , 6, 19		215
291	Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. <i>Hepatology</i> , <b>2018</b> , 67, 260-272	11.2	213
290	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 831-40	13.4	207
289	Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 333ra50	17.5	204
288	Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. <i>Hepatology</i> , <b>2014</b> , 59, 2286-98	11.2	171
287	Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 702-12	13.4	165
286	Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. <i>Gastroenterology</i> , <b>2015</b> , 149, 660-8.e1	13.3	144
285	Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 234-9	13.4	135
284	The carbon tetrachloride model in mice. <i>Laboratory Animals</i> , <b>2015</b> , 49, 4-11	2.6	134

283	FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. <i>Scientific Reports</i> , <b>2016</b> , 6, 33453	4.9	131
282	Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. <i>Gastroenterology</i> , <b>2016</b> , 150, 123-33	13.3	131
281	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , <b>2017</b> , 37, 694-699	7.9	128
280	The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 409-19	5.8	123
279	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 398-411	13.4	120
278	Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. <i>PLoS ONE</i> , <b>2011</b> , 6, e24568	3.7	118
277	Mechanisms of extrahepatic vasodilation in portal hypertension. <i>Gut</i> , <b>2008</b> , 57, 1300-14	19.2	114
276	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 842-854	13.4	108
275	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 688-701	13.4	102
274	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. <i>Scientific Reports</i> , <b>2015</b> , 5, 12931	4.9	92
273	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , <b>2019</b> , 157, 149-162	13.3	91
272	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , <b>2018</b> , 154, 1694-1705.e4	13.3	90
271	Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. <i>Liver International</i> , <b>2017</b> , 37, 396-405	7.9	90
270	Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. <i>Gastroenterology</i> , <b>2006</b> , 130, 838-54	13.3	89
269	G-Protein-Coupled Receptor MrgD Is a Receptor for Angiotensin-(1-7) Involving Adenylyl Cyclase, cAMP, and Phosphokinase A. <i>Hypertension</i> , <b>2016</b> , 68, 185-94	8.5	84
268	Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. <i>Hepatology</i> , <b>2014</b> , 60, 334-48	11.2	84
267	Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. <i>Laboratory Investigation</i> , <b>2012</b> , 92, 1440-50	5.9	82
266	Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. <i>Hepatology</i> , <b>2018</b> , 67, 1014-1026	11.2	81

265	Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. <i>Liver International</i> , <b>2011</b> , 31, 860-70	78	77
264	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 476	8.4	76
263	Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. <i>Gastroenterology</i> , <b>2013</b> , 145, 874-884.e5	13.3	76
262	HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 1220-7	13.4	75
261	Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. <i>Hepatology</i> , <b>2007</b> , 45, 495-506	11.2	75
260	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 57-65	13.4	74
259	Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , <b>2019</b> , 69, 282-293	11.2	73
258	Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1086-96	6.1	73
257	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1792-1800.e3	6.9	72
256	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , <b>2020</b> , 69, 1127-1138	19.2	70
255	Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. <i>Gut</i> , <b>2006</b> , 55, 1296-305	19.2	70
254	Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. <i>Hepatology</i> , <b>2008</b> , 47, 1264-76	11.2	69
253	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 399-411	18.8	66
252	Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 258-70	8.6	66
251	Circulating microbiome in blood of different circulatory compartments. <i>Gut</i> , <b>2019</b> , 68, 578-580	19.2	65
250	Statins: Old drugs as new therapy for liver diseases?. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 194-202	13.4	63
249	The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1735-43	4	58
248	Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. <i>Hepatology</i> , <b>2018</b> , 67, 1472-1484	11.2	57

247	Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 1218-25	2.2	55
246	Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 442-450	13.4	53
245	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. <i>Radiology</i> , <b>2018</b> , 288, 748-754	20.5	53
244	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1082-1091	13.4	52
243	Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. <i>Nature Immunology</i> , <b>2016</b> , 17, 593-603	19.1	52
242	Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. <i>Hepatology</i> , <b>2009</b> , 50, 1924-35	11.2	52
241	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 670-685	13.4	50
240	CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 332-9	13.4	48
239	Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. <i>Laboratory Investigation</i> , <b>2011</b> , 91, 241-51	5.9	48
238	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , <b>2020</b> , 72, 88-102	11.2	46
237	Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients. <i>Hepatology</i> , <b>2015</b> , 61, 46-55	11.2	45
236	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , <b>2019</b> , 69, 1686-1701	11.2	45
235	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. <i>Gut</i> , <b>2017</b> , 66, 145-155	19.2	44
234	Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. <i>Gut</i> , <b>2017</b> , 66, 507-518	19.2	44
233	Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. <i>Gut</i> , <b>2016</b> , 65, 1057-8	19.2	43
232	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 31-41	18.8	43
231	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , <b>2016</b> , 64, 224-31	11.2	42
230	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1140-1150	13.4	41

229	Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00025	4.2	41
228	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1097-1108	13.4	41
227	Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. <i>Hepatology</i> , <b>2017</b> , 66, 1232-1241	11.2	39
226	Statins improve NASH via inhibition of RhoA and Ras. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 311, G724-G733	5.1	38
225	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 963-973.e14	6.9	38
224	Smaller-Diameter Covered Transjugular Intrahepatic Portosystemic Shunt Stents Are Associated With Increased Survival. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2793-2799.e1	6.9	37
223	Novel role of nuclear receptor Rev-erb $\alpha$ in hepatic stellate cell activation: potential therapeutic target for liver injury. <i>Hepatology</i> , <b>2014</b> , 59, 2383-96	11.2	36
222	Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. <i>Scientific Reports</i> , <b>2015</b> , 5, 14573	4.9	36
221	High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173992	3.7	34
220	Prospective Evaluation of Passive Expansion of Partially Dilated Transjugular Intrahepatic Portosystemic Shunt Stent Grafts-A Three-Dimensional Sonography Study. <i>Journal of Vascular and Interventional Radiology</i> , <b>2017</b> , 28, 117-125	2.4	33
219	Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 584-92	2.4	33
218	Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. <i>Frontiers in Physiology</i> , <b>2013</b> , 4, 195	4.6	33
217	Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 437-447	6.1	33
216	Rationale for the use of statins in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , <b>2017</b> , 312, G407-G412	5.1	32
215	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , <b>2021</b> , 70, 379-387	19.2	32
214	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , <b>2021</b> , 160, 193-205.e10	13.3	32
213	Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 1027152	2.8	31
212	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , <b>2020</b> , 9,	7.9	30

211	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , <b>2018</b> , 2, 211-222	6	30
210	Does Transjugular Intrahepatic Portosystemic Shunt Stent Differentially Improve Survival in a Subset of Cirrhotic Patients?. <i>Seminars in Liver Disease</i> , <b>2018</b> , 38, 87-96	7.3	30
209	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1135-42	13.4	30
208	Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. <i>Gut</i> , <b>2015</b> , 64, 1349-50	19.2	30
207	Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. <i>European Journal of Clinical Investigation</i> , <b>2003</b> , 33, 1006-12	4.6	30
206	Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. <i>PLoS ONE</i> , <b>2013</b> , 8, e83341	3.7	29
205	Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 62, 31-47	12.7	29
204	Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. <i>Liver International</i> , <b>2005</b> , 25, 657-66	7.9	28
203	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , <b>2019</b> , 69, 1287-1299	11.2	28
202	Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 167-180	24.2	28
201	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , <b>2020</b> , 40, 1457-1466	7.9	27
200	PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. <i>PLoS ONE</i> , <b>2014</b> , 9, e108544	3.7	27
199	Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. <i>Liver International</i> , <b>2008</b> , 28, 331-8	7.9	27
198	Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. <i>Gut</i> , <b>2011</b> , 60, 1122-32	19.2	26
197	Is detection of bacterial DNA in ascitic fluid of clinical relevance?. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1487-94	2.2	26
196	JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. <i>Blood</i> , <b>2019</b> , 134, 1832-1846	2.2	25
195	Mouse models of metabolic liver injury. <i>Laboratory Animals</i> , <b>2015</b> , 49, 47-58	2.6	25
194	Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction?. <i>Liver Transplantation</i> , <b>2020</b> , 26, 906-915	4.5	25

193	Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. <i>Frontiers in Physiology</i> , <b>2015</b> , 6, 359	4.6	25
192	Etiology and Complications of Portal Vein Thrombosis. <i>Viszeralmedizin</i> , <b>2014</b> , 30, 375-80		25
191	The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 302, G873-87	5.1	25
190	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1362-1372	13.4	25
189	Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. <i>Liver International</i> , <b>2016</b> , 36, 386-94	7.9	25
188	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , <b>2021</b> , 75, 610-622	13.4	25
187	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , <b>2018</b> , 8, 9372	4.9	24
186	Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?. <i>Medicine (United States)</i> , <b>2015</b> , 94, e2127	1.8	24
185	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 69	8.4	23
184	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , <b>2021</b> , 75 Suppl 1, S67-S81	13.4	23
183	Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. <i>Liver International</i> , <b>2018</b> , 38, 875-884	7.9	23
182	Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases. <i>European Radiology</i> , <b>2019</b> , 29, 4709-4717	8.8	22
181	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. <i>Liver International</i> , <b>2020</b> , 40, 1435-1446	7.9	22
180	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. <i>Medicine (United States)</i> , <b>2018</b> , 97, e0462	1.8	22
179	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138732	3.7	22
178	Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. <i>Endoscopy International Open</i> , <b>2016</b> , 4, E1305-E1310	3	22
177	Assessment of response to beta-blockers by expression of Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1265-73	13.4	21
176	Increased myocardial contractility identifies patients with decompensated cirrhosis requiring liver transplantation. <i>Liver Transplantation</i> , <b>2018</b> , 24, 15-25	4.5	20



175	Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , <b>2018</b> , 34, 270-275	2.4	20
174	Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0116768	3.7	20
173	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 1660-1673	11.2	20
172	Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis. <i>Liver Transplantation</i> , <b>2018</b> , 24, 595-605	4.5	19
171	Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. <i>Gut</i> , <b>2018</b> , 67, 593-594	19.2	19
170	Interventional Treatment of Acute Portal Vein Thrombosis. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , <b>2018</b> , 190, 740-746	2.3	19
169	Portal vein thrombosis in patients with cirrhosis. <i>Gastroenterology Report</i> , <b>2017</b> , 5, 148-156	3.3	19
168	Predisposing Factors in Acute-on-Chronic Liver Failure. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 167-73	7.3	19
167	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 817-828	13.4	19
166	Combination of CCl with alcoholic and metabolic injuries mimics human liver fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 317, G182-G194	5.1	18
165	Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	18
164	The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. <i>PLoS ONE</i> , <b>2014</b> , 9, e103779	3.7	18
163	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. <i>Gut</i> , <b>2020</b> , 69, 1535-1536	19.2	18
162	Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 490, 643-649 <sup>3-4</sup>	3.4	17
161	Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 885-893	7.9	17
160	Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy. <i>Liver International</i> , <b>2015</b> , 35, 344-52	7.9	17
159	Managing portal hypertension in patients with liver cirrhosis. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	17
158	Future therapy of portal hypertension in liver cirrhosis - a guess. <i>F1000prime Reports</i> , <b>2014</b> , 6, 95		16

157	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , <b>2017</b> , 7, 10934	4.9	16
156	The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury. <i>Scientific Reports</i> , <b>2016</b> , 6, 28770	4.9	16
155	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , <b>2021</b> ,	19.2	16
154	Left Ventricular Longitudinal Contractility Predicts Acute-on-Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , <b>2019</b> , 3, 340-347	6	15
153	Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 568-579	6.1	15
152	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. <i>Oncotarget</i> , <b>2018</b> , 9, 36220-36237	3.3	15
151	Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties. <i>International Journal of Cardiology</i> , <b>2018</b> , 250, 21-28	3.2	15
150	Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. <i>Scientific Reports</i> , <b>2019</b> , 9, 2256	4.9	14
149	A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 329-339	6.1	14
148	Communications via the Small Leucine-rich Proteoglycans: Molecular Specificity in Inflammation and Autoimmune Diseases. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2020</b> , 68, 887-906	3.4	14
147	Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162144	3.7	14
146	Evolution of nodule stiffness might predict response to local ablative therapy: A series of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192897	3.7	13
145	Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191118	3.7	13
144	Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	13
143	Controlled underdilation using novel VIATORR <sup>®</sup> controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , <b>2021</b> , 3, 100264	10.3	13
142	Trust is good, control is better: technical considerations in blood microbiome analysis. <i>Gut</i> , <b>2020</b> , 69, 1362-1363	19.2	13
141	Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3456-64	4	12
140	Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. <i>Liver International</i> , <b>2020</b> , 40, 1701-1712	7.9	12

139	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2509-2526	15.9	12
138	Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. <i>Radiology</i> , <b>2020</b> , 297, 51-61	20.5	12
137	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00123	4.2	11
136	Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1627, 91-116	1.4	11
135	Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. <i>Nature Communications</i> , <b>2018</b> , 9, 4805	17.4	11
134	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1346-1354	13.4	11
133	Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease. <i>Gut</i> , <b>2017</b> , 66, 558-559	19.2	10
132	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. <i>Liver International</i> , <b>2019</b> , 39, 1514-1520	7.9	10
131	Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2018</b> , 19, 143	2.8	10
130	Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes. <i>Liver Transplantation</i> , <b>2020</b> , 26, 283-293	4.5	10
129	Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 1179-1185	2.2	10
128	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 342-350	13.4	10
127	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. <i>Scientific Reports</i> , <b>2017</b> , 7, 40556	4.9	9
126	Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. <i>HIV Medicine</i> , <b>2019</b> , 20, 230-236	2.7	9
125	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. <i>Liver International</i> , <b>2015</b> , 35, 1393-402	7.9	9
124	Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00223	4.2	9
123	The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices. <i>Advanced Materials</i> , <b>2021</b> , 33, e2006104	24	9
122	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139981	3.7	8

121	Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase?. <i>Liver International</i> , <b>2009</b> , 29, 933-41	7.9	8
120	The Development and Outcome of Acute-on-Chronic Liver Failure After Surgical Interventions. <i>Liver Transplantation</i> , <b>2020</b> , 26, 227-237	4.5	8
119	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 200-219	13.4	8
118	Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 7187836	4.6	8
117	Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. <i>JHEP Reports</i> , <b>2021</b> , 3, 100316	10.3	8
116	Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245091	3.7	8
115	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
114	Deficiency in four and one half LIM domain protein 2 (FHL2) aggravates liver fibrosis in mice. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 8	3	7
113	The Role of Decorin and Biglycan Signaling in Tumorigenesis.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 801801	5.3	7
112	Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 632502	4.6	7
111	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 75 Suppl 1, S14-S26	13.4	7
110	Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. <i>Liver International</i> , <b>2020</b> , 40, 186-193	7.9	7
109	Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. <i>European Radiology Experimental</i> , <b>2019</b> , 3, 22	4.5	6
108	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. <i>Hepatology</i> , <b>2019</b> , 70, 911-924	11.2	6
107	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 354	8.4	6
106	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1352	8.4	6
105	microRNA-200a: A stage-dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients. <i>Hepatology Communications</i> , <b>2017</b> , 1, 36-45	6	6
104	Diagnosis of megacystis-microcolon intestinal hypoperistalsis syndrome with aplastic desmosis in adulthood: a case report. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2008</b> , 20, 353-5	2.2	6

103	Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
102	Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model. <i>JHEP Reports</i> , <b>2021</b> , 3, 100367	10.3	6
101	Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression. <i>Gut</i> , <b>2017</b> , 66, 1540-1541	19.2	5
100	Reply to: "Adding embolization to TIPS implantation: A better therapy to control bleeding from ectopic varices?". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 202-203	13.4	5
99	Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , <b>2020</b> , 40, 2228-2241	7.9	5
98	Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?. <i>Hepatology</i> , <b>2016</b> , 64, 1792-1794	11.2	5
97	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. <i>Scientific Reports</i> , <b>2019</b> , 9, 11598	4.9	5
96	Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219526	3.7	5
95	"Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. <i>Minerva Gastroenterology</i> , <b>2018</b> , 64, 51-61	3	5
94	Hepatic inflammasome activation as origin of Interleukin-1 $\beta$ and Interleukin-1 $\alpha$ in liver cirrhosis. <i>Gut</i> , <b>2021</b> , 70, 1799-1800	19.2	5
93	Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
92	Biglycan: A regulator of hepatorenal inflammation and autophagy. <i>Matrix Biology</i> , <b>2021</b> , 100-101, 150-161	11.4	5
91	PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 699-708	6.1	5
90	Extracellular Matrix Remodeling in Chronic Liver Disease. <i>Current Tissue Microenvironment Reports</i> , <b>2021</b> , 2, 1-12	1.1	5
89	Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Read-out or reason?. <i>Hepatology</i> , <b>2016</b> , 63, 1729-32	11.2	5
88	Acute-on-chronic liver failure: a global disease. <i>Gut</i> , <b>2022</b> , 71, 5-6	19.2	5
87	Severe abnormal Heart Rate Turbulence Onset is associated with deterioration of liver cirrhosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195631	3.7	5
86	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1116-1127	13.4	5

85	A faecal microbiota signature with high specificity for pancreatic cancer.. <i>Gut</i> , <b>2022</b> ,	19.2	5
84	Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 464-465	13.4	4
83	Udenafil decreases portal pressure and improves erectile dysfunction in liver cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S471	13.4	4
82	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 980-982	13.4	4
81	Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
80	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. <i>Liver Transplantation</i> , <b>2020</b> , 26, 1652-1657	4.5	4
79	Serum Sphingosine-1-Phosphate Is Decreased in Patients With Acute-on-Chronic Liver Failure and Predicts Early Mortality. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1477-1486	6	4
78	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 927-928	6.1	4
77	Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. <i>JHEP Reports</i> , <b>2021</b> , 3, 100233	10.3	4
76	Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1784-1794	12.3	4
75	AngioJet-assisted transvenous-transhepatic mechanical thrombectomy in the portal vein. <i>Polish Journal of Radiology</i> , <b>2018</b> , 83, e536-e544	1.6	4
74	Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). <i>EClinicalMedicine</i> , <b>2021</b> , 40, 101116	11.3	4
73	Impact of Acute-on-Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, e54	3.3	3
72	Rho-kinase inhibition is beneficial in fibrosis. <i>Hepatology</i> , <b>2017</b> , 65, 1780-1781	11.2	3
71	Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
70	ErArrestin2 is increased in liver fibrosis in humans and rodents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 27082-27084	11.5	3
69	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
68	Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. <i>International Journal of Surgery</i> , <b>2020</b> , 75, 139-147	7.5	3

67	Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
66	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018).. <i>Lancet Regional Health - Europe, The</i> , <b>2022</b> , 12, 100240		3
65	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. <i>Liver International</i> , <b>2020</b> , 40, 3093-3102	7.9	3
64	Impact of transjugular intrahepatic portosystemic shunt creation on the central lymphatic system in liver cirrhosis. <i>Scientific Reports</i> , <b>2021</b> , 11, 7065	4.9	3
63	Reply to: Correspondence on The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiologyP <i>Journal of Hepatology</i> , <b>2021</b> , 74, 480-481	13.4	3
62	Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
61	Dynamic human liver proteome atlas reveals functional insights into disease pathways.. <i>Molecular Systems Biology</i> , <b>2022</b> , 18, e10947	12.2	3
60	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e16-e17	13.4	2
59	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222840	3.7	2
58	[342] ATORVASTATIN INHIBITS FIBROGENESIS THROUGH INHIBITION OF ACTIVATION OF HEPATIC STELLATE CELLS. <i>Journal of Hepatology</i> , <b>2007</b> , 46, S134	13.4	2
57	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	2
56	Alox12/15 Deficiency Exacerbates, While Lipoxin A Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1447	8.4	2
55	Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). <i>Scientific Reports</i> , <b>2020</b> , 10, 20682	4.9	2
54	Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acute-On-Chronic Liver Failure. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1265-1277	6	2
53	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100221	10.3	2
52	Acute Decompensation and Acute-on-Chronic Liver Failure. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 419-430	4.6	2
51	Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231701	3.7	2
50	Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , <b>2021</b> , 5, 650-660	6	2

49	Regulation of uridine diphosphate-glucuronosyltransferase 1A expression by miRNA-214-5p and miRNA-486-3p. <i>Epigenomics</i> , <b>2021</b> , 13, 271-283	4.4	2
48	Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study.. <i>Hepatology International</i> , <b>2022</b> , 1	8.8	2
47	Novel Targets and Drug Development in Portal Hypertension. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 187-196	1	1
46	Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 673-681	5.3	1
45	Prediction of presence of oesophageal varices just by shear-wave elastography of the liver and spleen. <i>Liver International</i> , <b>2017</b> , 37, 1406-1407	7.9	1
44	Early prediction of decompensation (EPOD) Score - non-invasive determination of liver cirrhosis decompensation risk.. <i>Liver International</i> , <b>2022</b> ,	7.9	1
43	Liver Failure, Acute-on-Chronic <b>2020</b> , 436-443		1
42	Variceal bleeding has increased mortality compared to nonvariceal bleeding only in males. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 33,	2.2	1
41	Akute Dekompensation und akut-auf-chronisches Leberversagen. <i>Gastroenterologe</i> , <b>2021</b> , 16, 179-185	0.1	1
40	Glue Embolization of Gastroesophageal Varices during Transjugular Intrahepatic Portosystemic Shunt (TIPS) Improves Survival Compared to Coil-only Embolization-A Single-Center Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , <b>2021</b> , 44, 1240-1250	2.7	1
39	Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia. <i>Gut</i> , <b>2021</b> , 70, 221-222	19.2	1
38	Evaluation of impact of elective invasive examinations in patients with transjugular intrahepatic portosystemic shunt in the long-term follow up. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 24-34	1.6	1
37	The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 715765	5.6	1
36	Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 3534-3538	11.2	1
35	Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 720898	4.6	1
34	Reply to: "The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites". <i>JHEP Reports</i> , <b>2021</b> , 3, 100349	10.3	1
33	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.. <i>Hepatology Communications</i> , <b>2021</b> ,	6	1
32	Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 831005	4.9	1



31	Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100442	10.3	o
30	Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 814496	6.9	o
29	Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 791574	5.7	o
28	Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?. <i>Gut</i> , <b>2022</b> , 71, 1036-1038	19.2	o
27	Nichtzirrhotische portale Hypertension Ursachen und praktisches Management. <i>Gastroenterologie</i> , <b>2021</b> , 16, 90-101	0.1	o
26	Role of circulating angiogenin levels in portal hypertension and TIPS. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256473	3.7	o
25	Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263989	3.7	o
24	Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure.. <i>Transplant International</i> , <b>2022</b> , 35, 10108	3	o
23	Cranial stent position is independently associated with the development of TIPS dysfunction.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3559	4.9	o
22	Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100448	10.3	o
21	TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis-A case series and review of the literature.. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0010065	4.8	o
20	Transplantation in Acute-on-Chronic Liver Failure: Feasibility and Futility. <i>Clinical Liver Disease</i> , <b>2022</b> , 19, 191-193	2.2	o
19	Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis. <i>Current Hepatology Reports</i> , <b>2016</b> , 15, 271-279	1	
18	Reply:. <i>Hepatology</i> , <b>2007</b> , 46, 1310-1310	11.2	
17	Severe alcoholic hepatitis as precipitant for organ failure and ACLF.. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2022</b> , 60, 67-76	1.6	
16	Variceal bleeding <b>2008</b> , 233-238		
15	Dynamic role of human ILC3 in the regulation of hepatic fibrogenesis. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, E2-E89	1.6	
14	Protective role of VEGF-A165b in liver cirrhosis with portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, E2-E89	1.6	

- 13 Novel rat model of repetitive portal venous embolization mimicking human non-cirrhotic idiopathic portal hypertension. *Zeitschrift Fur Gastroenterologie*, **2016**, 54, 1343-1404 1.6
- 12 Variceal bleeding **2009**, 174-180
- 11 Pre-primary and Primary Prophylaxis of Variceal Hemorrhage **2014**, 75-96
- 10 Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?. *Journal of Hepatology*, **2020**, 73, 977-979 13.4
- 9 Infektionen und Lebertransplantation. *Gastroenterologe*, **2021**, 16, 186-193 0.1
- 8 Microbiome and Nanotechnology: The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices (Adv. Mater. 18/2021). *Advanced Materials*, **2021**, 33, 2170139 24
- 7 Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. *JHEP Reports*, **2021**, 3, 100287 10.3
- 6 Animal Models When Examining the Gut-Liver Axis **2019**, 235-264
- 5 Gut-Liver-Brain axis in chronic liver disease with a focus on hepatic encephalopathy **2021**, 159-185
- 4 Effects of Ethanol Feeding in Early-Stage NAFLD Mice Induced by Western Diet. *Livers*, **2021**, 1, 27-39
- 3 Statine als Therapie bei Lebererkrankungen?. *Tumor Diagnostik Und Therapie*, **2018**, 39, 595-599 0.1
- 2 Statins After Variceal Bleeding Are Beneficial, but Still an Unexplained Mystery?. *Gastroenterology*, **2021**, 161, 2067-2068 13.3
- 1 Response to: Association of rectal colonization by mdros with new infection in cirrhosis.. *Journal of Hepatology*, **2022**, 13.4